Evidence map›Paper›PMID 41281481›Full record

ArticleWorld journal of gastrointestinal oncology2025

Evaluation of pancreatic adenocarcinoma with tumor budding and lymphocytic infiltration as prognostic marker.

Sunil V Jagtap, Shubham S Jagtap

Abstract readLetter
In one paragraph

Article in World journal of gastrointestinal oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Sunil V JagtapDepartment of Pathology, Krishna Vishwa Vidyapeeth, Krishna Institute of Medical Sciences, Karad 415110, Maharashtra, India. drsvjagtap@gmail.com.
Shubham S JagtapDepartment of Medicine, Krishna Vishwa Vidyapeeth, Krishna Institute of Medical Sciences, Karad 415110, Maharashtra, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is the most prevalent type of pancreatic neoplasm. It is a highly aggressive lethal malignancy related to its delayed in diagnosis and limited response to treatments. The incidence and mortality of pancreatic cancer have been increasing over the years. Tumor budding is a proven independent, adverse prognostic factor in PDAC. It is helpful for improvement of prognosis in PDAC in early and precise diagnostic modalities. Tumor budding should be conveyed in pathology reports and taken into account by future oncologic staging systems.

Indexed as

EvaluationPancreatic ductal adenocarcinomaPrognostic markerTumor BuddingTumor-infiltrating lymphocytes

Identifiers

PMID41281481
PMCPMC12635662

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.